Clinical Trial

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in patients with relapsed and refractory neuroblastoma (NB). Another goal of the study is to understand the function of the multi-CAR-T cells and their persistency in the patients.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-11-18; most recent amendment 2026-06-18.
Trial Details
NCT Number NCT04637503
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions Neuroblastoma
Enrollment 100 participants
Start Date 2026-06-01
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22